Fierce Biotech

UroGen hands anti-CTLA-4 drug back to Agenus after being unimpressed with phase 1 data

UroGen is handing an anti-CTLA-4 antibody back to Agenus after concluding phase 1 data for the bladder cancer drug didn’t ...
EurekAlert!

GLP-1 receptor agonists show anti-cancer benefits beyond weight loss

New research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) and published in the journal eClinicalMedicine finds that first generation weight-loss ...
Business Wire

Drug Farm and Xiamen Amoytop Biotech Co., Ltd. Enter into Option Agreement for First-In-Class Innate Immunity Agonist, DF-006 to Treat Hepatitis B and Hepatocellular Cancer

SHANGHAI, China & XIAMEN, China & ALBANY, N.Y.--(BUSINESS WIRE)--Drug Farm, a private biotechnology company utilizing genetics and artificial intelligence technologies to discover and develop ...
Hosted on MSN

Unveiling the Hidden Anti-Cancer Powers of GLP-1 Receptor Agonists Beyond Weight Loss

Can a diet pill treat cancer? There is fresh evidence that indicates type 2 diabetes and obesity medications GLP-1 receptor agonists (GLP-1RAs) have the unprecedented anti-cancer feature. The ...
Morningstar

Drug Farm and Xiamen Amoytop Biotech Co., Ltd. Enter into Option Agreement for First-In-Class Innate Immunity Agonist, DF-006 to Treat Hepatitis B and Hepatocellular Cancer

Drug Farm, a private biotechnology company utilizing genetics and artificial intelligence technologies to discover and develop innovative, immune-modulating therapies, today announced that it has ...